Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 3.12 -2.50% -0.08
PIRS closed down 2.5 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical PIRS trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 21 20 DMA Support Bullish -2.50%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -2.50%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.50%
Mar 18 Upper Bollinger Band Walk Strength -6.59%
Mar 18 Upper Bollinger Band Touch Strength -6.59%
Mar 15 180 Bullish Setup Bullish Swing Setup -6.02%
Mar 15 Upper Bollinger Band Walk Strength -6.02%

Older signals for PIRS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Medicine Chemistry Alpha Cancers Dialysis Asthma Chronic Kidney Disease Membrane Technology Inflammatory Diseases Anatomy End Stage Renal Disease Kidney Diseases Hepatology Kidney Hepcidin Treatment Of Various Types Of Cancers
Is PIRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.47
52 Week Low 2.39
Average Volume 348,221
200-Day Moving Average 4.2423
50-Day Moving Average 2.9644
20-Day Moving Average 3.132
10-Day Moving Average 3.24
Average True Range 0.1989
ADX 29.96
+DI 18.1116
-DI 12.1271
Chandelier Exit (Long, 3 ATRs ) 2.8833
Chandelier Exit (Short, 3 ATRs ) 3.4267
Upper Bollinger Band 3.3993
Lower Bollinger Band 2.8647
Percent B (%b) 0.48
BandWidth 17.068966
MACD Line 0.0697
MACD Signal Line 0.0754
MACD Histogram -0.0057
Fundamentals Value
Market Cap 138.24 Million
Num Shares 44.3 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -4.39
Price-to-Sales 31.97
Price-to-Book 22.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.48
Resistance 3 (R3) 3.49 3.39 3.42
Resistance 2 (R2) 3.39 3.29 3.38 3.40
Resistance 1 (R1) 3.25 3.24 3.20 3.24 3.38
Pivot Point 3.15 3.15 3.12 3.14 3.15
Support 1 (S1) 3.01 3.05 2.96 3.00 2.86
Support 2 (S2) 2.91 3.00 2.90 2.84
Support 3 (S3) 2.77 2.91 2.82
Support 4 (S4) 2.76